[
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts",
    "summary": "Johnson & Johnson (JNJ) closed at $154.42 in the latest trading session, marking a -0.63% move from the prior day.",
    "url": "https://finnhub.io/api/news?id=7ac468d5d454818592596774636290f4d4ed98e156bacaf81860c8b2d13c7f4a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748987115,
      "headline": "Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts",
      "id": 134999645,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) closed at $154.42 in the latest trading session, marking a -0.63% move from the prior day.",
      "url": "https://finnhub.io/api/news?id=7ac468d5d454818592596774636290f4d4ed98e156bacaf81860c8b2d13c7f4a"
    }
  },
  {
    "ts": null,
    "headline": "ASCO25: J&J’s trispecific antibody shows 100% response in Phase I multiple myeloma study",
    "summary": "First-in-human data for the trispecific antibody “suggest a paradigm shift” for the relapsed/refractory multiple myeloma space.",
    "url": "https://finnhub.io/api/news?id=ce8e1822d27d55a9f9e096725cc21aa8f33f7472166906730f8783b71cdecde7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748984269,
      "headline": "ASCO25: J&J’s trispecific antibody shows 100% response in Phase I multiple myeloma study",
      "id": 134999646,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "First-in-human data for the trispecific antibody “suggest a paradigm shift” for the relapsed/refractory multiple myeloma space.",
      "url": "https://finnhub.io/api/news?id=ce8e1822d27d55a9f9e096725cc21aa8f33f7472166906730f8783b71cdecde7"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson's Darzalex Faspro Regimen Improves Progression-Free Survival in Two Phase 3 Myeloma Trials",
    "summary": "Johnson & Johnson (JNJ) said Tuesday that data from two phase 3 trials show a Darzalex Faspro-based",
    "url": "https://finnhub.io/api/news?id=f32930aa0f8c39405d7df1e4d3b71f9766d7c62f3622818fb4fd1573305a1a8c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748965838,
      "headline": "Johnson & Johnson's Darzalex Faspro Regimen Improves Progression-Free Survival in Two Phase 3 Myeloma Trials",
      "id": 134987387,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) said Tuesday that data from two phase 3 trials show a Darzalex Faspro-based",
      "url": "https://finnhub.io/api/news?id=f32930aa0f8c39405d7df1e4d3b71f9766d7c62f3622818fb4fd1573305a1a8c"
    }
  },
  {
    "ts": null,
    "headline": "Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma",
    "summary": "Johnson & Johnson (NYSE:JNJ) announced today new long-term follow-up data from the Phase 1b/2 CARTITUDE-1 study demonstrating 33 percent (n=32) of patients in the study (n=97) with relapsed or refractory multiple myeloma (RRMM) treated with CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) achieved progression-free survival (PFS) of five years or more with a single infusion and no maintenance or subsequent anti-myeloma therapy.1 These data underscore Johnson & Johnson's dedication to advancing tr",
    "url": "https://finnhub.io/api/news?id=7371194365655bd726d16a65df6ecc8d0ffa6f8625fd7794f26e0e7d883d5af3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748961900,
      "headline": "Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma",
      "id": 134978822,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) announced today new long-term follow-up data from the Phase 1b/2 CARTITUDE-1 study demonstrating 33 percent (n=32) of patients in the study (n=97) with relapsed or refractory multiple myeloma (RRMM) treated with CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) achieved progression-free survival (PFS) of five years or more with a single infusion and no maintenance or subsequent anti-myeloma therapy.1 These data underscore Johnson & Johnson's dedication to advancing tr",
      "url": "https://finnhub.io/api/news?id=7371194365655bd726d16a65df6ecc8d0ffa6f8625fd7794f26e0e7d883d5af3"
    }
  },
  {
    "ts": null,
    "headline": "DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced data from two studies highlighting that a DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen demonstrated deep and sustained minimal residual disease (MRD) negativity rates, and improved long-term progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM), regardless of transplant status.1,2,3 Findings were highlighted as oral presentations of an analysis of sustained MRD in transplant-eligibl",
    "url": "https://finnhub.io/api/news?id=2a28b288d59bc09b5a89f399496bb495d703c71bb0bcc4b501596e810754fe89",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748961900,
      "headline": "DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity",
      "id": 134978819,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced data from two studies highlighting that a DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen demonstrated deep and sustained minimal residual disease (MRD) negativity rates, and improved long-term progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM), regardless of transplant status.1,2,3 Findings were highlighted as oral presentations of an analysis of sustained MRD in transplant-eligibl",
      "url": "https://finnhub.io/api/news?id=2a28b288d59bc09b5a89f399496bb495d703c71bb0bcc4b501596e810754fe89"
    }
  },
  {
    "ts": null,
    "headline": "Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients",
    "summary": "Johnson & Johnson announced today initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients with relapsed or refractory multiple myeloma. Among the 36 patients who received the recommended phase 2 dose (RP2D), the overall response rate (ORR) was 86.1 percent. In the 27 patients who were naive to BCMA and GPRC5D directed therapies, the ORR was 100 percent at the RP2D. Findings were featured in an oral presentation at the 2025 American Soci",
    "url": "https://finnhub.io/api/news?id=e38411cf9be58a3bd416171fe1db3f856b9a7163d6a936d4e34f9a4c9f16bddd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748961900,
      "headline": "Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients",
      "id": 134978818,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson announced today initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients with relapsed or refractory multiple myeloma. Among the 36 patients who received the recommended phase 2 dose (RP2D), the overall response rate (ORR) was 86.1 percent. In the 27 patients who were naive to BCMA and GPRC5D directed therapies, the ORR was 100 percent at the RP2D. Findings were featured in an oral presentation at the 2025 American Soci",
      "url": "https://finnhub.io/api/news?id=e38411cf9be58a3bd416171fe1db3f856b9a7163d6a936d4e34f9a4c9f16bddd"
    }
  },
  {
    "ts": null,
    "headline": "Why This 1 Value Stock Could Be a Great Addition to Your Portfolio",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finnhub.io/api/news?id=4e638002128a242854d0a30f2ee8c9ec319ec3052a86c763d02eb0a5d05d70c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748958010,
      "headline": "Why This 1 Value Stock Could Be a Great Addition to Your Portfolio",
      "id": 134978823,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
      "url": "https://finnhub.io/api/news?id=4e638002128a242854d0a30f2ee8c9ec319ec3052a86c763d02eb0a5d05d70c8"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Says Akeega Has Potential to Slow Castration-Sensitive Prostate Cancer Growth",
    "summary": "Johnson & Johnson (JNJ) said Tuesday that the first results from a phase 3 study showed that its Ake",
    "url": "https://finnhub.io/api/news?id=751545bb650ad1d157b08addf8b926929d4cc76ffdbc5625e35dbff23b0766f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748957412,
      "headline": "Johnson & Johnson Says Akeega Has Potential to Slow Castration-Sensitive Prostate Cancer Growth",
      "id": 134978825,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) said Tuesday that the first results from a phase 3 study showed that its Ake",
      "url": "https://finnhub.io/api/news?id=751545bb650ad1d157b08addf8b926929d4cc76ffdbc5625e35dbff23b0766f3"
    }
  },
  {
    "ts": null,
    "headline": "IVE: Value Has Been Lagging For A Decade",
    "summary": "IVE is the largest and most liquid S&P 500 Value Index ETF, with sector exposure in tech, financials, and healthcare. Read the report on its performance and other metrics.",
    "url": "https://finnhub.io/api/news?id=9c9452fcd9a14edd8ad74b9d27fd08b705aef70389876a4bbca857e9b87c070c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748953240,
      "headline": "IVE: Value Has Been Lagging For A Decade",
      "id": 134980073,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1457055342/image_1457055342.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "IVE is the largest and most liquid S&P 500 Value Index ETF, with sector exposure in tech, financials, and healthcare. Read the report on its performance and other metrics.",
      "url": "https://finnhub.io/api/news?id=9c9452fcd9a14edd8ad74b9d27fd08b705aef70389876a4bbca857e9b87c070c"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Announces Initial Phase 1 Results of JNJ-79635322 in Patients with Relapsed or Refractory Multiple Myeloma",
    "summary": "Johnson & Johnson announced initial Phase 1 results of JNJ-79635322 , a novel investigational trispecific antibody in patients with relapsed or refractory multiple myeloma. Among the 36 patients who...",
    "url": "https://finnhub.io/api/news?id=b82b9c9f1c2ba22f5f92e0a1d9958ae530f2e0b1e7920b643eccbe2a60dfd20b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748952336,
      "headline": "Johnson & Johnson Announces Initial Phase 1 Results of JNJ-79635322 in Patients with Relapsed or Refractory Multiple Myeloma",
      "id": 134978948,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announced initial Phase 1 results of JNJ-79635322 , a novel investigational trispecific antibody in patients with relapsed or refractory multiple myeloma. Among the 36 patients who...",
      "url": "https://finnhub.io/api/news?id=b82b9c9f1c2ba22f5f92e0a1d9958ae530f2e0b1e7920b643eccbe2a60dfd20b"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC",
    "summary": "Johnson & Johnson announced today first results from the Phase 3, randomized, double-blind, placebo-controlled AMPLITUDE study evaluating the combination of niraparib and abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR) genetic alterations including BRCA. The results show a clinically meaningful and statistically significant improvement in both radiographic progression-free survival (rPFS",
    "url": "https://finnhub.io/api/news?id=f41d5dd5c785b3d01562b2c830cab8bd8f607f94d4e6ac5737554060c0f9ce72",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748952000,
      "headline": "Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC",
      "id": 134978826,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson announced today first results from the Phase 3, randomized, double-blind, placebo-controlled AMPLITUDE study evaluating the combination of niraparib and abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR) genetic alterations including BRCA. The results show a clinically meaningful and statistically significant improvement in both radiographic progression-free survival (rPFS",
      "url": "https://finnhub.io/api/news?id=f41d5dd5c785b3d01562b2c830cab8bd8f607f94d4e6ac5737554060c0f9ce72"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Announces New Long-Term Follow-Up Data from the Phase 1B/2 Cartitude-1 Study Demonstrating 33% of Patients in the Study Demonstrating 33% (N=97) with Relapsed or Refractory Multiple Myeloma",
    "summary": "Johnson & Johnson announced new long-term follow-up data from the Phase 1b/2 CARTITUDE-1 study demonstrating 33% of patients in the study with relapsed or refractory multiple myeloma treated with...",
    "url": "https://finnhub.io/api/news?id=441f6f7fc41569a0dabfe80ae2f74a471cc786698ec18d355346a27e9b0903a9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748951439,
      "headline": "Johnson & Johnson Announces New Long-Term Follow-Up Data from the Phase 1B/2 Cartitude-1 Study Demonstrating 33% of Patients in the Study Demonstrating 33% (N=97) with Relapsed or Refractory Multiple Myeloma",
      "id": 134978422,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announced new long-term follow-up data from the Phase 1b/2 CARTITUDE-1 study demonstrating 33% of patients in the study with relapsed or refractory multiple myeloma treated with...",
      "url": "https://finnhub.io/api/news?id=441f6f7fc41569a0dabfe80ae2f74a471cc786698ec18d355346a27e9b0903a9"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Announces Data from Two Studies Highlighting DARZALEX FASPRO® (Daratumumab and Hyaluronidase-Fihj)",
    "summary": "Johnson & Johnson announced data from two studies highlighting that a DARZALEX FASPRO® -based quadruplet regimen demonstrated deep and sustained minimal residual disease negativity rates, and...",
    "url": "https://finnhub.io/api/news?id=8a46694dfa237b87fbea1546a3739b4a9d8f37e73c476471043210c5a1489cfc",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748951428,
      "headline": "Johnson & Johnson Announces Data from Two Studies Highlighting DARZALEX FASPRO® (Daratumumab and Hyaluronidase-Fihj)",
      "id": 134978425,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announced data from two studies highlighting that a DARZALEX FASPRO® -based quadruplet regimen demonstrated deep and sustained minimal residual disease negativity rates, and...",
      "url": "https://finnhub.io/api/news?id=8a46694dfa237b87fbea1546a3739b4a9d8f37e73c476471043210c5a1489cfc"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Announces First Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled AMPLITUDE Study",
    "summary": "highlighting the potential of the combination in this patient population to delay both cancer progression and the worsening of symptoms.1 This marks the first Phase 3 data to show clinical improvement...",
    "url": "https://finnhub.io/api/news?id=f2eaf9018a46ba1166673bc1a890616a4c87b36aa29949b7498bfcc12af8120b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748950675,
      "headline": "Johnson & Johnson Announces First Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled AMPLITUDE Study",
      "id": 134978309,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "highlighting the potential of the combination in this patient population to delay both cancer progression and the worsening of symptoms.1 This marks the first Phase 3 data to show clinical improvement...",
      "url": "https://finnhub.io/api/news?id=f2eaf9018a46ba1166673bc1a890616a4c87b36aa29949b7498bfcc12af8120b"
    }
  },
  {
    "ts": null,
    "headline": "J&J: promising results against prostate cancer",
    "summary": "Johnson & Johnson announces positive top-line results from a Phase 3 study evaluating the combination of niraparib + abiraterone acetate + prednisone in patients with metastatic castration-sensitive...",
    "url": "https://finnhub.io/api/news?id=2f2657f129d8568380964931cc0222fce8d9d1777b32ce903439d5a3e3153bc9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748944973,
      "headline": "J&J: promising results against prostate cancer",
      "id": 134977410,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announces positive top-line results from a Phase 3 study evaluating the combination of niraparib + abiraterone acetate + prednisone in patients with metastatic castration-sensitive...",
      "url": "https://finnhub.io/api/news?id=2f2657f129d8568380964931cc0222fce8d9d1777b32ce903439d5a3e3153bc9"
    }
  },
  {
    "ts": null,
    "headline": "How leading oncology drugmakers set the stage for future advances",
    "summary": "Drugmakers like J&J and Astellas are looking beyond today’s cancer treatments for the windows of opportunity decades down the road.",
    "url": "https://finnhub.io/api/news?id=07323cbf5ad5bb322fc629619e8c34a86811adead5c8ae607e2e8ebda26e5a4d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748937600,
      "headline": "How leading oncology drugmakers set the stage for future advances",
      "id": 134978827,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Drugmakers like J&J and Astellas are looking beyond today’s cancer treatments for the windows of opportunity decades down the road.",
      "url": "https://finnhub.io/api/news?id=07323cbf5ad5bb322fc629619e8c34a86811adead5c8ae607e2e8ebda26e5a4d"
    }
  }
]